Table 1.
Clinicopathological characteristics of the patients used for discovering and evaluating the metastatic fingerprint
| Discovery | Evaluation | |
|---|---|---|
| Race | 545 | 904 |
| European American | 545(100%) | 734(81.2%) |
| African American | 0 | 57(6.31%) |
| Others | 0 | 10(1.11%) |
| NA | 0 | 103(11.4%) |
| Patient age (yr) | ||
| Median [range] | 66 [47, 79] | 61 [37.3, 83] |
| Pre‐operative PSA | ||
| Pre‐PSA<10 | 286(51.91%) | 371(41.04%) |
| 10<= pre‐PSA<20 | 118(21.42%) | 158(17.48%) |
| Pre‐PSA>20 | 132(23.96%) | 86(9.51%) |
| NA | 15(2.72%) | 289(31.97%) |
| Path GS | ||
| <=6 | 64(11.62%) | 170(18.81%) |
| 7 | 275(49.91%) | 521(57.63%) |
| 8 | 68(12.34%) | 100(11.06%) |
| >=9 | 144(26.13%) | 110(12.17%) |
| NA | 0(0%) | 3(0.33%) |
| EPE | ||
| Positive | 276(50.09%) | 378(41.81%) |
| NA | 0(0%) | 242(26.77%) |
| SVI | ||
| Positive | 177(32.12%) | 173(19.14%) |
| NA | 0(0%) | 239(26.44%) |
| SM | ||
| Positive | 270(49%) | 364(40.27%) |
| NA | 0(0%) | 99(10.95%) |
| LNI | ||
| Positive | 73(13.25%) | 60(6.64%) |
| NA | 0(0%) | 79(8.74%) |
| Met | ||
| Positive | 215(39.02%) | 148(16.37%) |
| NA | 0(0%) | 191(21.13%) |
| BCR | ||
| Positive | 393(71.32%) | 275(30.42%) |
| NA | 0(0%) | 191(21.13%) |
Overall, about 61% of patients manifest with adverse pathologic findings, and patients are mostly of European descent.